The GRPR Antagonist [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

The GRPR Antagonist [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists were developed for SPECT and PET imaging of prostate cancer. We previously reported a preclinical evaluation of the GRPR...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Ayman Abouzayed, Jesper Borin, Fanny Lundmark, Anastasiya Rybina, Sophia Hober, Roman Zelchan, Vladimir Tolmachev, Vladimir Chernov, Anna Orlova
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2023-05-01
Saila:Diagnostics
Gaiak:
prostate cancer
GRPR antagonist
technetium-99m
sterility
toxicity testing
Sarrera elektronikoa:https://www.mdpi.com/2075-4418/13/9/1611

Internet

https://www.mdpi.com/2075-4418/13/9/1611

Antzeko izenburuak